{"transactions":[{"id":802618,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2026-04-22T16:17:53.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":37100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 20, 2026 (the \"Grant Date\"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date."}],"balance_after":37100,"derivative":{"exercise_price":2.36,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":37100},"source":{"system":"sec-edgar","filing":"0001104659-26-046835","document":"tm2612397-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465926046835/tm2612397-2_4seq1.xml","form_type":"4"}},{"id":1280173,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2025-02-06T17:46:58.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 5, 2025, the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest immediately."}],"balance_after":250000,"derivative":{"exercise_price":0.7982,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-25-010180","document":"tm255798-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465925010180/tm255798-2_4seq1.xml","form_type":"4"}},{"id":1306449,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants for Common Stock","published_at":"2025-01-08T16:31:33.000Z","date":"2025-01-06","kind":"purchase","planned":false,"acquired":true,"shares":49261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock."}],"balance_after":49261,"derivative":{"exercise_price":0.9,"exercise_date":"2025-01-07","expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":49261},"source":{"system":"sec-edgar","filing":"0001104659-25-002052","document":"tm252665-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465925002052/tm252665-4_4seq1.xml","form_type":"4"}},{"id":1306448,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-08T16:31:33.000Z","date":"2025-01-06","kind":"purchase","planned":false,"acquired":true,"shares":49261,"price":1.015,"value":49999.915,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc."}],"balance_after":1097458,"source":{"system":"sec-edgar","filing":"0001104659-25-002052","document":"tm252665-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465925002052/tm252665-4_4seq1.xml","form_type":"4"}},{"id":1549051,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2024-04-03T21:56:33.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 23, 2024 (the \"Grant Date\"), the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person."}],"balance_after":250000,"derivative":{"exercise_price":3.15,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-24-043293","document":"tm2411025-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465924043293/tm2411025-2_4seq1.xml","form_type":"4"}},{"id":1687419,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants for Common Stock","published_at":"2024-01-04T16:24:50.000Z","date":"2024-01-03","kind":"exercise","planned":false,"acquired":false,"shares":19737,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.55,"exercise_date":"2023-01-27","expiration_date":"2024-01-27","underlying":"Common Stock","underlying_shares":19737},"source":{"system":"sec-edgar","filing":"0001104659-24-001373","document":"tm242052-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465924001373/tm242052-1_4seq1.xml","form_type":"4"}},{"id":1687418,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-04T16:24:50.000Z","date":"2024-01-03","kind":"exercise","planned":false,"acquired":true,"shares":19737,"price":3.55,"value":70066.35,"ownership":{"direct":true},"balance_after":1048197,"source":{"system":"sec-edgar","filing":"0001104659-24-001373","document":"tm242052-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465924001373/tm242052-1_4seq1.xml","form_type":"4"}},{"id":1992760,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2023-02-24T16:31:40.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 13, 2023 (the \" Grant Date\"), the Reporting Person was granted stock options to purchase 130,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person."}],"balance_after":130000,"derivative":{"exercise_price":3.41,"expiration_date":"2033-02-12","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001104659-23-025334","document":"tm237745-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465923025334/tm237745-2_4seq1.xml","form_type":"4"}},{"id":2200066,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants for Common Stock","published_at":"2022-07-29T17:01:37.000Z","date":"2022-07-27","kind":"purchase","acquired":true,"shares":19737,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19737,"derivative":{"exercise_price":3.55,"exercise_date":"2023-01-27","expiration_date":"2028-01-27","underlying":"Common Stock","underlying_shares":19737},"source":{"system":"sec-edgar","filing":"0001104659-22-084315","document":"tm2222169-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465922084315/tm2222169-1_4seq1.xml","form_type":"4"}},{"id":2200065,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants for Common Stock","published_at":"2022-07-29T17:01:37.000Z","date":"2022-07-27","kind":"purchase","acquired":true,"shares":19737,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19737,"derivative":{"exercise_price":3.55,"exercise_date":"2023-01-27","expiration_date":"2024-01-27","underlying":"Common Stock","underlying_shares":19737},"source":{"system":"sec-edgar","filing":"0001104659-22-084315","document":"tm2222169-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465922084315/tm2222169-1_4seq1.xml","form_type":"4"}},{"id":2200064,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-29T17:01:37.000Z","date":"2022-07-27","kind":"purchase","acquired":true,"shares":19737,"price":3.8,"value":75000.6,"ownership":{"direct":true},"balance_after":1028460,"source":{"system":"sec-edgar","filing":"0001104659-22-084315","document":"tm2222169-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465922084315/tm2222169-1_4seq1.xml","form_type":"4"}},{"id":2500473,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-22T16:05:34.000Z","date":"2021-11-19","kind":"purchase","acquired":true,"shares":5200,"price":4.8,"value":24960.0,"ownership":{"direct":true},"balance_after":1008723,"source":{"system":"sec-edgar","filing":"0001104659-21-142471","document":"tm2133703-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465921142471/tm2133703-1_4seq1.xml","form_type":"4"}},{"id":2640867,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2021-07-06T16:06:41.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 1, 2021 (the \"Employment Agreement Grant Date\"), the Reporting Person was granted stock options to purchase 500,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's President and Chief Executive Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024."}],"balance_after":500000,"derivative":{"exercise_price":6.18,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-21-089396","document":"tm2121425-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465921089396/tm2121425-3_4seq1.xml","form_type":"4"}},{"id":2640866,"issuer":{"id":8195,"kind":"organization","name":"Acurx Pharmaceuticals, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2021-07-06T16:06:41.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 29, 2021 (the \"June Grant Date\"), the Reporting Person was granted stock options to purchase 350,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person."}],"balance_after":350000,"derivative":{"exercise_price":6.26,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001104659-21-089396","document":"tm2121425-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1271123/000110465921089396/tm2121425-3_4seq1.xml","form_type":"4"}},{"id":3836510,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-08-22T21:08:36.000Z","date":"2018-08-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units vest on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units vest on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000921895-18-002460","document":"form410211008luc_082018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000092189518002460/form410211008luc_082018.xml","form_type":"4"}},{"id":3836509,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2018-08-22T21:08:36.000Z","date":"2018-08-20","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1.53,"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000921895-18-002460","document":"form410211008luc_082018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000092189518002460/form410211008luc_082018.xml","form_type":"4"}},{"id":4347477,"issuer":{"id":129056,"kind":"organization","name":"PLx Pharma Inc.","symbol":"PLXP"},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2017-04-21T21:30:30.000Z","date":"2017-04-19","kind":"disposition_to_issuer","acquired":false,"shares":298826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."},{"field":"shares","element":"transactionShares","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."}],"balance_after":0,"derivative":{"exercise_price":13.93,"exercise_date":"2014-03-18","expiration_date":"2019-03-18","underlying":"Common Stock","underlying_shares":298826},"source":{"system":"sec-edgar","filing":"0001144204-17-021599","document":"v464776_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1497504/000114420417021599/v464776_4.xml","form_type":"4"}},{"id":4347476,"issuer":{"id":129056,"kind":"organization","name":"PLx Pharma Inc.","symbol":"PLXP"},"owners":[{"id":51613,"kind":"person","name":"LUCI DAVID P","position":1,"cik":"0001271123","reported_name":"LUCI DAVID P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2017-04-21T21:30:30.000Z","date":"2017-01-17","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."},{"field":"shares","element":"transactionShares","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the \"Merger\") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the \"Company\") on April 18, 2017."}],"balance_after":275000,"derivative":{"exercise_price":1.8,"expiration_date":"2022-01-17","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001144204-17-021599","document":"v464776_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1497504/000114420417021599/v464776_4.xml","form_type":"4"}}]}